Abbott India Ltd.
NSE: ABBOTINDIA · Pharmaceuticals
Snapshot
Unlock Abbott India Ltd.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Abbott India Limited is a prominent pharmaceutical company that provides a diverse portfolio of healthcare products across therapeutic areas including gastroenterology, metabolic health, and women's health. Headquartered in Mumbai, the company operates as a subsidiary of Abbott Capital India Limited.
Business Model
The company generates revenue through the marketing and distribution of a wide range of pharmaceutical products and consumer health solutions within the Indian market. It leverages the global research and development capabilities of its parent organisation to maintain a strong product pipeline.
- Incorporation Year:1944
Growth Outlook
Growth is expected to be driven by the company's strong presence in chronic therapeutic segments and the increasing demand for high-quality healthcare products in India. Continued focus on expanding its portfolio in metabolic and central nervous system treatments remains a key strategic priority.
Key Risks
- Regulatory Pricing Controls. The company is subject to stringent price control regulations by the National Pharmaceutical Pricing Authority, which can impact profit margins.
- Supply Chain Disruptions. Dependence on global supply chains for active pharmaceutical ingredients exposes the company to potential logistical and geopolitical risks.
- Intense Market Competition. The Indian pharmaceutical sector is highly fragmented and competitive, requiring constant investment in marketing and product differentiation.
Start your research today
Unlock AI insights, financials, peers and live data on Abbott India Ltd. and 5,000+ companies — free.
Key Metrics
REVENUE
₹7,004 Cr
TTM · standalone
NET PROFIT
₹1,615 Cr
TTM · standalone
EPS
₹759.85
TTM · standalone
RETURN ON EQUITY
35.9%
TTM · standalone
RETURN ON CAPITAL EMPLOYED
45.8%
TTM · standalone
P/E
35.3×
Q1 FY27 · standalone
EV/EBITDA
25.1x
Q1 FY27 · standalone
EBITDA MARGIN
32.3%
TTM · standalone
NET PROFIT MARGIN
23.6%
Q1 FY27 · standalone
DEBT TO EQUITY
0.0x
Q1 FY27 · standalone
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E (TTM) | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Abbott India Ltd.ABBOTINDIA | ₹57,235 Cr | 35.3× | 25.13 | 6.3% | 32.3% | 35.9% | 45.8% | -10.2% |
Alkem Laboratories Ltd.ALKEM | ₹64,774 Cr | 28.9× | 18.21 | 13.4% | 24.1% | 17.1% | 20.5% | -4.4% |
Biocon Ltd.BIOCON | ₹64,026 Cr | 109.0× | 19.83 | 9.8% | 22.2% | 1.5% | 3.0% | +7.0% |
Ipca Laboratories Ltd.IPCALAB | ₹49,792 Cr | 37.6× | 20.87 | 10.6% | 23.7% | 18.3% | 19.4% | +46.4% |
Glaxosmithkline Pharmaceuticals Ltd.GLAXO | ₹48,736 Cr | 44.7× | 31.78 | 5.8% | 37.9% | 50.6% | 61.2% | +2.7% |
Gland Pharma Ltd.GLAND | ₹48,007 Cr | 42.0× | 21.67 | 17.6% | 30.8% | 11.6% | 15.7% | +45.1% |
As of Q1 FY27
Financials
Abbott India Ltd.
NSE: ABBOTINDIA · Pharmaceuticals
Snapshot
Unlock Abbott India Ltd.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Abbott India Limited is a prominent pharmaceutical company that provides a diverse portfolio of healthcare products across therapeutic areas including gastroenterology, metabolic health, and women's health. Headquartered in Mumbai, the company operates as a subsidiary of Abbott Capital India Limited.
Business Model
The company generates revenue through the marketing and distribution of a wide range of pharmaceutical products and consumer health solutions within the Indian market. It leverages the global research and development capabilities of its parent organisation to maintain a strong product pipeline.
- Incorporation Year:1944
Growth Outlook
Growth is expected to be driven by the company's strong presence in chronic therapeutic segments and the increasing demand for high-quality healthcare products in India. Continued focus on expanding its portfolio in metabolic and central nervous system treatments remains a key strategic priority.
Key Risks
- Regulatory Pricing Controls. The company is subject to stringent price control regulations by the National Pharmaceutical Pricing Authority, which can impact profit margins.
- Supply Chain Disruptions. Dependence on global supply chains for active pharmaceutical ingredients exposes the company to potential logistical and geopolitical risks.
- Intense Market Competition. The Indian pharmaceutical sector is highly fragmented and competitive, requiring constant investment in marketing and product differentiation.
Start your research today
Unlock AI insights, financials, peers and live data on Abbott India Ltd. and 5,000+ companies — free.
Key Metrics
REVENUE
₹7,004 Cr
TTM · standalone
NET PROFIT
₹1,615 Cr
TTM · standalone
EPS
₹759.85
TTM · standalone
RETURN ON EQUITY
35.9%
TTM · standalone
RETURN ON CAPITAL EMPLOYED
45.8%
TTM · standalone
P/E
35.3x
Q1 FY27 · standalone
EV/EBITDA
25.1x
Q1 FY27 · standalone
EBITDA MARGIN
32.3%
TTM · standalone
NET PROFIT MARGIN
23.6%
Q1 FY27 · standalone
DEBT TO EQUITY
0.0x
Q1 FY27 · standalone
Peers · Pharmaceuticals
As of Q1 FY27